VistaGen Therapeutics Inc./$VTGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
- Ticker
- $VTGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 41
- Headquarters
- South San Francisco, United States
- Website
- www.vistagen.com
VTGN Metrics
BasicAdvanced
$8.1M
-
-$1.66
0.33
-
Price and volume
Market cap
$8.1M
Beta
0.33
52-week high
$5.14
52-week low
$0.16
Average daily volume
961K
Financial strength
Current ratio
3.066
Quick ratio
2.835
Long term debt to equity
0.003
Total debt to equity
0.032
Profitability
EBITDA (TTM)
-69.459
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,703.72%
Operating margin (TTM)
-2,785.69%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-83.21%
Return on equity (TTM)
-166.46%
Valuation
Price to revenue (TTM)
2.99
Price to book
0.33
Price to tangible book (TTM)
0.33
Price to free cash flow (TTM)
-0.12
Free cash flow yield (TTM)
-834.38%
Free cash flow per share (TTM)
-1.528
Growth
Revenue change (TTM)
287.15%
Earnings per share change (TTM)
-7.35%
3-year revenue growth (CAGR)
90.79%
3-year earnings per share growth (CAGR)
-36.80%
10-year earnings per share growth (CAGR)
-39.96%
What the Analysts think about VTGN
Analyst ratings (Buy, Hold, Sell) for VistaGen Therapeutics Inc. stock.
Analyst projections of the future price of VistaGen Therapeutics Inc. stock.
VTGN Financial Performance
Revenues and expenses
VTGN Earnings Performance
Company profitability
Upcoming events
No upcoming events
VTGN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.